With the AAV market gaining momentum, gene therapy developers are under increasing pressure to advance their AAV-based therapeutics for clinical trials quickly, while managing the risks and the time-consuming steps of gene therapy drug development. Leveraging Lonza expertise and the same tools and technologies implemented for our platform process, you can balance risk and speed, while maintaining high AAV productivity.

Latest content

Latest briefing from the Knowledge Center